While direct evidence with tirzepatide is limited, there have been post-marketing reports of ileus and intestinal obstruction with GLP-1 receptor agonists, warranting caution in patients with known strictures or obstructive symptoms
5 You get a two-fer: Some of the practices that help with PMOS also make a difference when it comes to menopausal symptoms and chronic condition risk management - healthy eating, consistent physical activity, getting 7 - 9 hours of high-quality sleep per night, managing stress, weight loss, and regular human connection
774780, pa
Both medications achieve clinically significant weight reduction, but tirzepatide demonstrates greater efficacy with 15-22% weight loss versus Qsymia's 6-10% in head-to-head comparisons
SingleCare Services, LLC is the marketer of the discount medical plan organization including its website, singlecare.com , with its corporate office located at 99 High Street, Suite 2800, Boston, MA 02110